• HOME
  • ABOUT US
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
ProAxsis technology highlighted in AJRCCM editorial
Share
Announcements, ProteaseTag®

ProAxsis technology highlighted in AJRCCM editorial

May 17, 2017
-
Posted by Webmaster

ProAxsis Ltd is delighted to observe that its ProteaseTag® Active Neutrophil Elastase Immunoassay is prominently featured in the most recent edition of the American Journal for Respiratory and Critical Care Medicine (AJRCCM). A prospective cohort study led by Dr James Chalmers at the University of Dundee has shown that sputum neutrophil elastase (NE) activity is a biomarker of disease severity and future risk of exacerbation in adults with bronchiectasis. This study involved more than 380 patients with bronchiectasis, who were followed over three years and utilised ProAxsis’ ProteaseTag® Active NE Immunoassay to assess neutrophil elastase activity. The study was previously published online, but has now been included in the May 2017 printed edition of this prestigious journal.

Alongside the article is an editorial authored by Professor Guy Brusselle and Dr Eve Van Braeckel from Ghent University in Belgium. The editors highlight the fact that during the 3-year follow-up, high sputum NE activity was independently associated with future exacerbation rate, hospital admissions and lung function decline. They conclude that Dr Chalmers and colleagues have demonstrated that sputum NE activity is associated not only with clinical and radiological severity of the disease but also with its activity, as evidenced by an increased risk for exacerbations and lung function decline.

Both the article itself and the corresponding editorial, can be accessed on the AJRCCM website. As previously announced, ProAxsis will be presenting further updates on its ProteaseTag® technology at the American Thoracic Society Conference taking place in Washington DC, on May 19th-24th.

Any queries concerning ProAxsis’ Immunoassay for measuring active neutrophil elastase, or any requests for support with measuring other active protease biomarkers using the Company’s proprietary ProteaseTag® technology, can be directed to info@proaxsis.com.

May 17, 2017
No comments yet

Related News

Other posts that you should not miss.
Announcements, News, Trials

ProAxsis’ Active Neutrophil Elastase Immunoassay highlighted in Stanford University trial

June 19, 2017
-
Posted by Webmaster

ProAxsis was delighted to see its ProteaseTag® technology incorporated in to an important study presented at the …

Read More
June 19, 2017
Posted by Webmaster
News, ProteaseTag®

ProAxsis CEO to present update at Bio-Europe Spring

March 6, 2017
-
Posted by Webmaster

Dr David Ribeiro, CEO of ProAxsis, will be attending the Bio-Europe Spring meeting, taking place in Barcelona on …

Read More
March 6, 2017
Posted by Webmaster
Announcements, News, ProteaseTag®

ProAxsis successfully licenses additional intellectual property from The Queen’s University of Belfast

May 10, 2017
-
Posted by Webmaster

ProAxsis Limited (www.proaxsis.com) is delighted to announce that it has secured a second licensing agreement with the Queen’s …

Read More
May 10, 2017
Posted by Webmaster
← PREVIOUS POST
ProAxsis CEO to present at Anglonordic Conference
NEXT POST →
ProAxsis successfully licenses additional intellectual property from The Queen’s University of Belfast

Leave a Comment

Your feedback is valuable for us. Your email will not be published.
Cancel Reply

Please wait...
Submit Comment

Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis supports next generation of scientists
    October 25, 2019

    ProAxsis was delighted to support the recent School of Pharmacy Undergraduate Awards at Queen’s …

  • ProAxsis welcomes Professor Stephen Smith as new Chairman
    October 25, 2019

    ProAxsis is pleased to confirm that Professor Stephen Smith has become the Chairman …

  • New data demonstrates high potential of NEATstik® as a rapid point-of-care monitoring tool for lung diseases
    June 3, 2019

    Positive early data from the BRIDGE1 study, a three-year 1000+ patient study in …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • November 18, 2019
    ProAxsis shortlisted for Small Business of the Year Award
  • October 25, 2019
    ProAxsis supports next generation of scientists
  • October 25, 2019
    ProAxsis welcomes Professor Stephen Smith as new Chairman
LATEST TWEETS
Twitter
ProAxsis
Follow Me
@TimFerguson01 https://t.co/00k2mJHY4o
8 days ago
- ProAxsis
Having a great night and delighted to be shortlisted at the #AIBBEawards @eye_business
8 days ago
- ProAxsis
RT @geinarsson: Recommended preprint by Alison Dicker et al. from @ProfJDChalmers group in Dundee on "The Sputum Microbiome Is Associated w…
24 days ago
- ProAxsis
RT @ProfJDChalmers: In summary- lower microbiome diversity means more exacerbations, more lung inflammation and a higher risk of mortality…
25 days ago
- ProAxsis
Copyright © 2016-2018 - ProAxsis - All rights reserved. 
ProAxsis technology highlighted in AJRCCM editorial | ProAxsis